Asia FX muted, dollar nurses losses as Trump tariffs take effect
Investing.com - Jefferies raised its price target on SI-BONE Inc. (NASDAQ:SIBN) to $28.00 from $27.00 while maintaining a Buy rating following the company’s second-quarter results.
The medical device company reported second-quarter revenue of $48.6 million, representing 22% growth and exceeding consensus estimates by 1%. U.S. revenue specifically grew by 23% during the quarter.
SI-BONE’s U.S. active surgeons increased by approximately 290 or 25% to around 1,440, which Jefferies noted continues to serve as a leading indicator for growth.
The company achieved positive cash flow of $1.1 million, well ahead of plans, while maintaining positive EBITDA of $1 million during the quarter.
Jefferies cited "continued broad based momentum driven by the portfolio" as giving confidence in SI-BONE’s performance in both the near and intermediate term, leading to the price target increase.
In other recent news, Si-Bone Inc. reported its second-quarter 2025 earnings, surpassing analyst expectations with an earnings per share (EPS) of -$0.14 compared to the forecast of -$0.18, resulting in a 22.22% surprise. The company’s revenue also exceeded projections, reaching $48.6 million against the anticipated $46.72 million. These results highlight Si-Bone’s stronger-than-expected financial performance for the quarter. No information about mergers or acquisitions was provided. Additionally, there were no analyst upgrades or downgrades mentioned in the recent developments. Other significant company news was not reported. These recent developments provide a factual overview of Si-Bone’s financial achievements in the latest quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.